The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.

Publication Type	Academic Article
Authors	McBride M, Pulice J, Beird H, Ingram D, D'Avino A, Shern J, Charville G, Hornick J, Nakayama R, Garcia-Rivera E, Araujo D, Wang W, Tsai J, Yeagley M, Wagner A, Futreal P, Khan J, Lazar A, Kadoch C
Journal	Cancer Cell
Volume	33
Issue	6
Pagination	1128-1141.e7
Date Published	05/31/2018
ISSN	1878-3686
Keywords	Chromatin, Oncogene Proteins, Fusion, SMARCB1 Protein, Sarcoma, Synovial
Abstract	Synovial sarcoma (SS) is defined by the hallmark SS18-SSX fusion oncoprotein, which renders BAF complexes aberrant in two manners: gain of SSX to the SS18 subunit and concomitant loss of BAF47 subunit assembly. Here we demonstrate that SS18-SSX globally hijacks BAF complexes on chromatin to activate an SS transcriptional signature that we define using primary tumors and cell lines. Specifically, SS18-SSX retargets BAF complexes from enhancers to broad polycomb domains to oppose PRC2-mediated repression and activate bivalent genes. Upon suppression of SS18-SSX, reassembly of BAF47 restores enhancer activation, but is not required for proliferative arrest. These results establish a global hijacking mechanism for SS18-SSX on chromatin, and define the distinct contributions of two concurrent BAF complex perturbations.
DOI	10.1016/j.ccell.2018.05.002
PubMed ID	29861296
PubMed Central ID	PMC6791822